Novavax, Inc. (NASDAQ: NVAX) is having yet another strong day in the market today, and for good reason. We’re nearing the end of the month of February, and that means that data is coming soon. This, in combination with the idea that a takeover is just around the corner, continues to send the stock screaming upward. Today, we’ll talk about what’s happening, what we’re seeing from NVAX, and what we’ll be watching for ahead.
NVAX Has Data Coming Soon
One of the big factors that is causing Novavax to make a run for the top at the moment is the fact that the company is set to release data any time now. In fact, according to news released by the company back in December, the next round of data should be released at some point this month. Given the fact that there are only 8 days left in this month, one can say that a catalyst is just over the horizon!
NanoFlu is a very important candidate for NVAX. At the end of the day, previous data suggest that the vaccine is overwhelmingly powerful when it comes to preventing the flu. In particular, NanoFlu has shown some data that suggest that it will work against flu strains that other already approved treatments have a hard time combating. So, not only could this be a new treatment that hits the market, but it could prove to revolutionize the way that we see flu prevention, and that would be a very big deal.
Another reason that NVAX has been headed for the top as of late is takeover speculation. The reality is that there are a couple of big players with deep pockets playing on the flu-vaccination ball court. In particular, various reports have pointed to Sanofi (NYSE: SNY) and GlaxoSmithKline (NYSE: GSK) as potential suitors for the company.
It makes sense. The reality is that both of these Goliaths of the biotech sector have approved vaccines for the flu on the market today. The only problem is that flu seasons continue to get worse as these vaccines seem to be losing their efficacy, and that’s seriously painful for the bottom line. On the other hand, we have Novavax, a company that is in the process of developing a treatment that could prove to be far better than any other flu vaccine on the market. That’s going to make the big guys shake in their boots a bit. However, with a market cap of well under $800 million, one of these big guys could easily acquire the company, taking control of the effective vaccine that’s likely to be the goose that lays the golden egg down the line.
What We’re Seeing From The Stock
As mentioned above, NVAX has been on a bit of a run toward the top as of late. However, it’s not for nothing! The reality is that a data release is just around the corner surrounding a vaccine that has already shown some very strong early data. Considering this, a positive catalyst is likely just around the corner. This, in combination with the potential of a larger competitor taking the company over, is causing investors to buy Novavax shares like they’re going out of style. So, it’s no surprise to see that the stock is heading up yet again. At the moment (8:58), NVAX is trading at $2.47 per share after a gain of $0.13 per share (5.56%) thus far today.
Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!
What We’ll Be Watching For Ahead
Moving forward, the CNA Finance team will continue to keep a close eye on NVAX. In particular, we’re interested in following the ongoing development of NanoFlu and excited to see the next round of results. We’re also following the rest of the company’s clinical pipeline, with a special interest in their RSV vaccine. Finally, we’re keeping our eyes peeled for any takeover news, as this is definitely a prime candidate. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!
Never Miss The News Again
Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!